Higher satisfaction and adherence with glatiramer acetate [amount hidden] TIW vs [amount hidden] QD in RRMS

What Was Tested

Researchers studied Glatiramer Acetate in this randomized controlled trial publication.

This trial was registered with ClinicalTrials.gov (NCT02499900).

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Patients (N = 861) were randomly assigned 1:1 to receive GA20 (n = 430) or GA40 (n = 431) during the core phase.

The primary endpoint was patient-reported medication satisfaction using the Medication Satisfaction Questionnaire (MSQ).

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

Random assignment meant chance, not the researchers, decided who got Glatiramer Acetate and who got the comparison, which limits bias.

Nothing was hidden in this open-label Glatiramer Acetate study: the participants and staff both knew the treatment.

Groups ran in parallel: each of the participants stayed in one arm throughout.

CONFIDENCE was a Phase 4, interventional, open-label, randomized, 2-arm, parallel-group, global study with a duration of 6 months.

Secondary endpoints included self-reported convenience perception using the Treatment Satisfaction Questionnaire for Medication-9 convenience component, symptomatic changes (Modified Fatigue Impact Scale, MFIS), and Mental Health Inventory (MHI).

Treatment adherence was measured by Multiple Sclerosis Treatment Adherence Questionnaire.

Results from the core phase were included.

What Was Measured

Topics PubMed links to this paper include Glatiramer Acetate, Immunosuppressive Agents, Medication Adherence, Multiple Sclerosis, Relapsing-Remitting and Patient Satisfaction.

The authors tagged it with the keywords Clinical trial, Copaxone, Patient satisfaction glatiramer acetate and Relapsing-remitting multiple sclerosis.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Glatiramer Acetate.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Multiple sclerosis and related disorders), a journal based in Netherlands.

More context: the Glatiramer Acetate compound page, all human trials.